Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand.

ABSTRACT:

Background

Azacitidine (AZA) plus venetoclax (VEN) has emerged as a widely accepted treatment option for acute myeloid leukemia (AML), particularly in older patients or those unfit for intensive chemotherapy. However, real-world data on AZA + VEN efficacy and safety in Southeast Asia remain limited.

Objectives

To evaluate the real-world effectiveness and safety of AZA + VEN in newly diagnosed (ND) and relapsed/refractory (R/R) AML patients in Thailand.

Design

A retrospective observational multicenter study.

Methods

This is a multicenter retrospective study included ND and R/R AML patients treated between 2021 and 2024 at three tertiary hospitals in Thailand. All patients received AZA at 75 mg/m² for 7 days per cycle. VEN dosing and duration were indi

SUBMITTER: Rattanathammethee T 

PROVIDER: S-EPMC12423537 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature